Patient P-02505
Therapy response
Stable
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 47 NP-02 recommended — Dietary Support Protocol NP-02
- Day 48 Patient accepted — Started NP-02 in the companion
- Day 58 GI symptom burden −28% vs expected — Dietary Support Protocol NP-02
- Day 64 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 64 Tolerance state changed — Unstable → Improving
- Day 71 GI-04 recommended — GI Support Protocol GI-04
- Day 72 Patient accepted — Started GI-04 in the companion
- Day 80 No meaningful change — GI Support Protocol GI-04
What changed?
Trajectory began diverging from predicted response on Day 64.
Primary contributors, last 14 days
- GI instability+14
- Inflammatory activity+6
- Treatment adherence-5
- Nutritional resilience-4
- Toxicity-4
What helped?
- Dietary Support Protocol NP-02Day 47Result: symptom burden −28%
- GI Support Protocol GI-04Day 71Result: no meaningful change
LIFE OS recommendation
Monitoring Escalation ME-01
83%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 25/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↓65
- WearableResting HR 76 bpm
- Wearable3,907 steps/day
- WearableShort sleep window
- Inflammatory signalling ↑60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 62
- WearableHRV 19 ms, trending down
- Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 73 and rising
- Drug metabolism and exposure ↑20
- BloodToxicity index 49
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.9 · butyrate capacity 25/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 19 ms
- Sleep
- 5.9 h
- Steps
- 3,848
- Resting HR
- 77 bpm
Daily log: GI score 73, nutritional resilience 35, adherence 37.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02552 | 18% | S07 | AD-05 | no change | 29 |
| P-02093 | 17% | S05 | AD-05 | no change | 40 |
| P-02483 | 19% | S06 | BR-03 | no change | 64 |
| P-02087 | 17% | S01 | BR-03 | no change | 40 |
| P-02151 | 33% | S04 | CR-01 | improved | 49 |
| P-02025 | 31% | S15 | CR-01 | improved | 61 |
| P-02054 | 28% | S01 | CR-01 | improved | 57 |
| P-02009 | 26% | S08 | CR-01 | improved | 64 |
| P-02154 | 25% | S16 | CR-01 | improved | 57 |
| P-02233 | 24% | S16 | CR-01 | improved | 66 |
| P-02395 | 19% | S12 | DT-01 | improved | 57 |
| P-02274 | 18% | S15 | DT-01 | improved | 50 |